María Villamayor

Instituto Cajal

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Alfredo Carrato

Instituto Cajal

Víctor Albarrán

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Pablo Reguera

Universidad de Sevilla

MÁ

María Ángeles Vaz Salgado

Hospital Universitario Ramón y Cajal

Ainhoa Madariaga

Research Institute Hospital 12 de Octubre

Pilar Garrido

Hospital Universitario Ramón y Cajal

Diana Isabel Rosero

Instituto Cajal

Luis Gorospe

Hospital Universitario Ramón y Cajal

Olga Martínez‐Sáez

Hospital Clínic de Barcelona

María Gión

Instituto Cajal

Cooperative Institutions

Hospital Universitario Ramón y Cajal

Instituto Cajal

Instituto Ramón y Cajal de Investigación Sanitaria

Centro de Investigación Biomédica en Red de Cáncer

Universidad de Alcalá

Instituto de Salud Carlos III

Hospital Universitario 12 De Octubre

Hospital Clínico San Carlos

Institut Català d'Oncologia

Instituto de Investigación Sanitaria de Santiago

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Current Landscape of Immunotherapy for Advanced Sarcoma

Cancers (2023)

Víctor Albarrán María Villamayor Javier Pozas Jesús Chamorro Diana Isabel Rosero

There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine–kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research.

Synovial Sarcoma

Adoptive immunotherapy

10.3390/cancers15082287

Cite

Citations (10)

Spinal Intramedullary Ewing Sarcoma with Meningeal Carcinomatosis: A Complete Response to Chemotherapy and Neuroaxis Irradiation. Case Report and Review of Literature

Journal of Cancer Science and Clinical Therapeutics (2023)

Víctor Albarrán María Villamayor Ignacio Ruz Jesús Vicente Chamorro Diana Isabel Rosero

Intramedullary Ewing sarcoma of the spinal cord is an extremely rare form of extraosseous Ewing sarcoma, with few cases reported in the literature. Given its rarity and the great difficulty in generating scientific evidence, there are no specific recommendations for its management, which is usually extrapolated from the guidelines for bone Ewing sarcomas. Aspects such as the preferred chemotherapy scheme and the indication of whole neuroaxis irradiation remain unanswered. We report the case of an 18-year-old patient with a spinal intramedullary Ewing sarcoma and a leptomeningeal relapse after surgery, who achieved a complete clinical and radiological response to chemotherapy with VDC/IE protocol and craniospinal irradiation.

Ewing's sarcoma

10.26502/jcsct.5079195

Cite

Citations (0)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas

International Journal of Molecular Sciences (2022)

Víctor Albarrán María Villamayor Jesús Chamorro Diana Isabel Rosero Javier Pozas

Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the young population. Few options of systemic treatment are available once they become unresectable and resistant to conventional chemotherapy. A better knowledge of the key role that tyrosine kinase receptors (VEGFR, RET, MET, AXL, PDGFR, KIT, FGFR, IGF-1R) may play in the pathogenesis of these tumors has led to the development of multi-target inhibitors (TKIs) that are progressively being incorporated into our therapeutic arsenal. Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical trials (cabozantinib, regorafenib, apatinib, sorafenib, and lenvatinib). Although the development of TKIs for other primary bone tumors is less advanced, preclinical data and early trials have begun to show their potential benefit in advanced Ewing sarcoma (ES) and rarer bone tumors (chondrosarcoma, chordoma, giant cell tumor of bone, and undifferentiated pleomorphic sarcoma). Previous reviews have mainly provided information on TKIs for OS and ES. We aim to summarize the existing knowledge regarding the use of TKIs in all bone sarcomas including the most recent studies as well as the potential synergistic effects of their combination with other systemic therapies.

Apatinib

Cabozantinib

Regorafenib

Bone Sarcoma

Bone cancer

Lenvatinib

10.3390/ijms232213784

Cite

Citations (20)

Gastrostomy vsnasogastric tube feeding in patients with head and neck cancer during radiotherapy alone or combined chemoradiotherapy

Nutrición Hospitalaria (2017)

Ainara Soria Elisa Santacruz Belén Vega-Piñeiro María Gión Javier Molina

Patients with head and neck cancer (HNC) submitted to radiotherapy alone or combined chemoradiotherapy present a high prevalence of malnutrition at baseline. Prophylactic use of gastrostomy has been suggested for these patients for delivering enteral nutrition. On the other hand, other authors have failed to demonstrate the effectiveness of this measure over nasogastric tube feeding.We studied 40 patients with HNC with moderate or severe malnutrition who were offered either prophylactic percutaneous gastrostomy before starting oncologic treatment or close follow-up with nutritional counseling with the placement of a nasogastric tube when necessary.There were no significant changes throughout the study period in weight (p = 0.338), body mass index (BMI) (p = 0.314) or serum proteins (p = 0.729), and these changes showed no differences between the gastrostomy vsnasogastric tube feeding groups. The amount of delivered energy was above the estimated energy needs with both gastrostomy and nasogastric tube feeding, but there were no differences in the total energy provided by enteral nutrition between groups. Patients in the gastrostomy group received enteral nutrition support for a longer period of time (p = 0.007).Both gastrostomy and nasogastric tube feeding are effective methods of delivering enteral nutrition in patients with HNC submitted to radiotherapy alone or combined chemoradiotherapy, with no differences between them in terms of avoiding further nutritional deterioration.

Gastrostomy tube

Percutaneous endoscopic gastrostomy

Enteral administration

Feeding tube

Chemoradiotherapy

10.20960/nh.680

Cite

Citations (15)

P1.01-004 Is There Any Role of Residential Radon in Non-Small Cell Lung Cancer (NSCLC) Patients Harboring Molecular Alterations?

Journal of Thoracic Oncology (2017)

Laura Mezquita Amparo Benito María Eugenia Olmedo Pablo Reguera Ainhoa Madariaga

10.1016/j.jtho.2016.11.528

Cite

Citations (0)

Systemic Treatment in Glioblastoma

IntechOpen eBooks (2023)

María Ángeles Vaz Salgado Sonia del Barco Berrón Raquel Luque María Villamayor Juan Manuel Sepúlveda-Sánchez

Glioblastoma is the most common primary brain tumor and the initial treatment with maximal safe resection is not curative. In order to improve the prognosis, surgery is completed with radiotherapy and temozolomide, an oral chemotherapy, but overall survival remains poor. Therefore, new efforts are needed to improve these results. In fact, different systemic treatments have been tested but, nevertheless, few advances have been reached despite the development of large clinical trials. This chapter will review the most important findings, achievements, and main studies in this pathology. Standard of care in newly diagnosed and recurrent glioblastoma will be reassessed with the results of clinical trials with targeted agents and immunotherapy. Ongoing studies are evaluating advanced treatments, with chimeric antigen receptor T-cells, biospecific T-cell antibodies, tumor vaccines, and oncolytic viruses, although results are pending, a wide review of these new-generation agents is important to better understand the advances in glioblastoma in the coming years.

Temozolomide

10.5772/intechopen.109243

Cite

Citations (0)

Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma.

PubMed (1998)

Manuel Pérez‐Encinas María Villamayor Antônio Hugo José Fróes Marques Campos Marta Sonia González José Belló

We studied the value of soluble CD25, CD8, CD23, CD54 and CD44 serum levels as tumor burden markers in lymphoma. Soluble CD25 compared with the others sCD and the usual serum factors (albumin, lactate dehydrogenase, beta 2-microglobulin, uric acid and C-reactive protein), showed the strongest correlation with the Ann Arbor stage and the number of affected localizations. sCD25 level is the most sensitive serum marker for tumor burden in lymphoma.

CD23

Beta-2 microglobulin

Source

Cite

Citations (16)

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

Clinical Lung Cancer (2019)

Laura Mezquita Amparo Benito Alberto Ruano‐Raviña Javier Zamora María Eugenia Olmedo

10.1016/j.cllc.2019.04.009

Cite

Citations (11)

1915 Comparison of local clinical subtyping to central molecular classification using microarray-based gene expression test in early breast cancer patients

European Journal of Cancer (2015)

A Cortés Margarita Fernández Noelia Martínez-Jáñez E.M. Guerra Enrique Guillén López

Subtyping

10.1016/s0959-8049(16)30864-4

Cite

Citations (0)

Recurrent Glioblastoma: A Review of the Treatment Options

Cancers (2023)

Maria Angeles Vaz-Salgado María Villamayor Víctor Albarrán V. Navarro Pilar Sotoca

Glioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5-10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been considered in several studies, mainly with alkylating agents, with data mostly from phase II studies. On the other hand, multiple studies have been carried out with target-directed treatments. Bevacizumab, a monoclonal antibody with anti-angiogenic activity, has demonstrated activity in several studies, and the FDA has approved it for this indication. Several other TKI drugs have been evaluated in this setting, but no clear benefit has been demonstrated. Immunotherapy treatments have been shown to be effective in other types of tumors, and several studies have evaluated their efficacy in this disease, both immune checkpoint inhibitors, oncolytic viruses, and vaccines. This paper reviews data from different studies that have evaluated the efficacy of different forms of relapsed glioblastoma.

10.3390/cancers15174279

Cite

Citations (37)